ReviewLeukemia2013
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Review in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Extramedullary disease in multiple myeloma: a systematic literature review.Blood cancer journal · 2022Pooled it
- Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.Current medical science · 2018Pooled it
- A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.Transplantation and cellular therapy · 2023Trial
- Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.Bone marrow transplantation · 2022Trial
- Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.Blood cancer journal · 2018Trial
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.Blood cancer journal · 2016Trial
- Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.Bone marrow transplantation · 2016Trial
- Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.Oncotarget · 2015Trial
- Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.Blood advances · 2026Article
- Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia.Haematologica · 2026Article
- Uncommon initial presentation of a gastric mass in a patient with primary plasma cell leukemia: a case report.BMC gastroenterology · 2026Article
- Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026Review
- Article
- Combined chemotherapy with sequential allogeneic hematopoietic stem cell transplantation successfully treats primary plasma cell leukemia: a case report.Frontiers in oncology · 2026Article
- Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia.Blood cancer journal · 2025Article
- [Chinese expert consensus on the diagnosis and treatment of plasma cell leukemia (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Development and validation of a prognostic staging system for primary plasma cell leukemia.Journal of hematology & oncology · 2025Article
- Diagnosis and Treatment of Plasmablastic Lymphoma in an Immunocompetent Patient: A Report of a Rare Case.Cureus · 2025Article
- Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders.Hematology reports · 2025Review
117 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
Abstract
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage (≥ 20%) and absolute number (≥ 2 × 10(9)/l) of plasma cells in the peripheral blood. It is proposed that the thresholds for diagnosis be re-examined and consensus recommendations are made for diagnosis, as well as, response and progression criteria. Induction therapy needs to begin promptly and have high clinical activity leading to rapid disease control in an effort to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens are recommended followed by high-dose therapy with autologous stem cell transplantation if feasible. Allogeneic transplantation can be considered in younger patients. Prospective multicenter studies are required to provide revised definitions and better understanding of the pathogenesis of PCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.